Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Urothelial03 study of datopotamab deruxtecan plus platinum versus gemcitabine plus platinum in advanced or metastatic urothelial cancer after EV plus pembrolizumab
CTR20254314Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan in transitional cell carcinoma (TCC), bladder cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on CTR20254314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254314.